Markets
About
Savara is an inhalation drug development company. Our lead product addresses an unmet clinical need in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis (CF) and in other high risk patient populations. MRSA is a growing problem, with a 6 year reduction in life expectancy for infected CF patients and no suitable treatment. The product is in preparation for its first human clinical trial.